Shattuck Labs, Inc. SEC Filings

Shattuck Labs CFO Andrew R. Neill purchased 64,027 shares and received 64,027 accompanying warrants in a private placement that closed on August 25, 2025. The combined price paid for each share plus warrant was $0.8677, and the warrants have an exercise price of $1.0846. After the transaction the reporting person beneficially owned 237,473 shares. The warrants are exercisable any time after issuance until 30 days following public disclosure of specified Phase 1 clinical trial data and the planned Phase 2 design for SL-325.

Insider purchase reported: Clay B. Siegall, a director of Shattuck Labs, Inc. (STTK), participated in a private placement that closed on August 25, 2025, acquiring 128,054 shares of common stock and accompanying warrants to buy up to 128,054 additional shares. The combined price for one share plus its accompanying warrant was $0.8677. The warrants have an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 SL-325 trial data and the planned Phase 2 design.

Insider purchase and warrant grant reported for Shattuck Labs (STTK). Taylor Schreiber, the company’s Chief Executive Officer and a director, participated in a private placement that closed on August 25, 2025, acquiring 25,610 shares of common stock at $0.8677 per share and receiving accompanying warrants to buy up to 25,610 shares. After the transaction Schreiber directly owns 96,612 shares. Schreiber also holds an indirect interest of 2,610,750 shares through Houghton Capital Holdings, LLC. The warrants are exercisable until the 30th day after the issuer publicly announces specific Phase 1 clinical trial data and planned Phase 2 design.

Shattuck Labs insider purchase reported. The company's Chief Technical Officer, Abhinav A. Shukla, acquired 5,122 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025 at a combined purchase price of $0.8677 per share with accompanying warrant. The filing also notes Shukla beneficially owns 81,258 shares after the transaction, which includes 600 shares purchased via the 2020 Employee Stock Purchase Plan on February 15, 2025 and 2,000 shares under the ESPP on August 15, 2025. The warrants cover 5,122 shares exercisable upon public disclosure of Phase 1 clinical trial data and planned Phase 2 design.

Redmile Group and affiliated funds acquired warrants and pre-funded warrants in Shattuck Labs' private placement (PIPE) closed August 25, 2025, increasing their reported economic exposure to 6,379,095 shares of common stock, representing 9.99% of the outstanding class on the stated calculation basis.

The Redmile Funds paid approximately $3,555,190 in aggregate to purchase Pre-Funded Warrants and Common Warrants at a combined purchase price of $0.8676, with RBI II contributing approximately $1,777,211. The filing details registration rights for resale of Common Stock issuable on exercise and describes a Beneficial Ownership Blocker that limits actual exercises to prevent ownership above 9.99%.

Redmile Group, LLC and Jeremy Green reported acquisitions of equity-linked securities of Shattuck Labs, Inc. (STTK) in a private placement closing on August 25, 2025. Institutional investors managed by Redmile received 4,097,730 pre-funded warrants and 4,097,730 common warrants tied to the same number of common shares at a combined purchase price of $0.8676 for each paired unit. The pre-funded warrants are exercisable immediately, carry a 9.99% beneficial ownership blocker and have no expiration; the accompanying common warrants expire 30 days after a public announcement of Phase 1 clinical data and Phase 2 design. Redmile and Jeremy Green disclaim beneficial ownership except to the extent of pecuniary interest. Michael Lee resigned from the issuer’s board effective the Closing Date.

Shattuck Labs (STTK) reported lower operating losses and trimmed R&D activity as it pivots to its DR3 antagonist program SL-325. Cash and cash equivalents were $50.5 million and total assets were $64.4 million at June 30, 2025, while accumulated deficit stood at $407.9 million. For the six months ended June 30, 2025 the company recognized a net loss of $26.2 million, an improvement from $40.1 million a year earlier, driven by a reduction in research and development expense after winding down SL-172154 activities and completing collaboration services in 2024.

Management states current cash is sufficient to fund operations for at least twelve months. The company expects to initiate enrollment in a Phase 1 trial of SL-325 in the third quarter of 2025 and complete enrollment in the full Phase 1 by the second quarter of 2026. In a subsequent event, Shattuck announced a securities purchase agreement expected to provide approximately $46 million in upfront gross proceeds upon closing following IND clearance for SL-325, with additional potential proceeds if warrants are exercised.

Shattuck Labs, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025. The 8-K states the press release is provided as Exhibit 99.1 and clarifies that the information is furnished (not "filed") for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except by specific reference. The filing confirms the company trades as STTK on The Nasdaq Global Select Market and that it is designated as an emerging growth company.

The 8-K contains no financial figures or discussion of results within the form itself and provides an exhibit listing and signature by CEO Dr. Taylor Schreiber. No additional operational or transaction details are included in this report.